CALA · Calithera Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $6.75M | $3.00M | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | $6.45M | $7.76M | $9.57M | - | $11.56M | $12.82M | $15.34M | - | $18.16M |
| SG&A | - | $3.08M | $3.62M | $4.26M | - | $6.34M | $4.49M | $5.43M | - | $4.74M |
| Total Operating Expenses | - | $9.53M | $11.38M | $13.83M | - | $17.90M | $17.31M | $20.77M | - | $22.90M |
| D&A | - | - | - | $64.0K | - | - | - | $73.0K | - | - |
| Operating Income | - | ($9.53M) | ($11.38M) | ($13.83M) | - | ($11.15M) | ($14.31M) | ($20.77M) | - | ($22.90M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | ($9.80M) | ($9.08M) | ($13.84M) | - | ($11.17M) | ($14.31M) | ($20.39M) | - | ($22.73M) |
| EPS - Basic | - | ($2.01) | ($3.86) | - | - | - | - | - | - | - |
| EPS - Diluted | - | ($2.01) | ($3.86) | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $25.45M | $34.07M | $41.79M | $44.66M | $59.54M | $84.49M | $92.20M | $101.35M | $107.15M | $120.58M |
| Accounts Receivable | - | - | - | $127.0K | - | $12.0K | $12.0K | $1.03M | $1.54M | $466.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $732.0K | $1.01M | $990.0K | $2.12M | $3.65M | $2.97M | $1.53M | $1.64M | $1.99M | $2.64M |
| Current Assets | $26.62M | $34.70M | $42.82M | $47.27M | $61.45M | $86.33M | $93.99M | $106.51M | $118.70M | $140.04M |
| Total Assets | $28.68M | $37.08M | $45.56M | $50.24M | $64.76M | $89.97M | $97.86M | $110.66M | $125.59M | $147.71M |
| Current Liabilities | $7.39M | $9.23M | $8.89M | $11.38M | $14.01M | $13.53M | $12.48M | $13.79M | $18.40M | $19.80M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $8.28M | $10.70M | $10.31M | $12.67M | $15.67M | $15.55M | $14.85M | $16.50M | $23.22M | $25.11M |
| Stockholders' Equity | $20.39M | $26.39M | $35.25M | ($3.14M) | $8.38M | $74.42M | $83.01M | $94.16M | $102.37M | $122.60M |
| Retained Earnings | ($512.62M) | ($505.68M) | ($495.88M) | ($505.16M) | ($491.33M) | ($422.12M) | ($410.94M) | ($396.63M) | ($376.24M) | ($353.67M) |
Cash Flow
| Line item | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($16.01M) | - | - | - | ($22.00M) | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | $6.50M | - | - |
| Financing Cash Flow | - | - | - | $1.14M | - | - | - | $9.54M | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | -165.2% | -476.9% | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | -165.5% | -477.0% | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | 171.2% | 427.3% | - | - | - |
| SG&A / Revenue | - | - | - | - | - | 94.0% | 149.6% | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -26.4% | -19.9% | -27.5% | - | -12.4% | -14.6% | -18.4% | - | -15.4% |
| Return on equity | - | -37.1% | -25.7% | 441.2% | - | -15.0% | -17.2% | -21.7% | - | -18.5% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.60 | 3.76 | 4.81 | 4.16 | 4.39 | 6.38 | 7.53 | 7.72 | 6.45 | 7.07 |
| Quick ratio | 3.60 | 3.76 | 4.81 | 4.16 | 4.39 | 6.38 | 7.53 | 7.72 | 6.45 | 7.07 |
| Cash ratio | 3.44 | 3.69 | 4.70 | 3.93 | 4.25 | 6.24 | 7.39 | 7.35 | 5.82 | 6.09 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.41 | 1.41 | 1.29 | -16.02 | 7.73 | 1.21 | 1.18 | 1.18 | 1.23 | 1.20 |
| Liabilities / Assets | 0.29 | 0.29 | 0.23 | 0.25 | 0.24 | 0.17 | 0.15 | 0.15 | 0.18 | 0.17 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | 0.08 | 0.03 | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | 1d | 1d | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | -2.4% | -44.0% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | 14.6% | 20.5% | 33.4% | - | 51.3% | 31.1% | 17.2% | - | -8.4% |
| Net income growth (YoY) | - | 12.3% | 36.6% | 32.2% | - | 50.9% | 29.8% | 16.6% | - | -12.0% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 143.3% | -64.5% | -57.5% | - | -91.8% | -39.3% | -42.1% | -26.2% | -28.1% | 1.6% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Calithera Biosciences against the 5 most active filers in the same SIC group.